The study, conducted by the Korea Disease Control and Prevention Agency in South Korea, involved 499 medical workers. One hundred people received one shot of each vaccine, 200 got two doses of Pfizer’s shot, and the rest got two doses of AstraZeneca’s shot.
The results showed that those who got the combination of shots had the same number of neutralizing antibodies as those who got two Pfizer shots, according to The Hill.
The study could lead to countries combining AstraZeneca’s shot with an mRNA vaccine to improve results, The Hill reported. AstraZeneca’s shot is used widely in many countries, but isn’t approved in the U.S.
A separate study conducted in June by British scientists showed that a combination of AstraZeneca and Pfizer’s shots produce the best T-cell and antibody response to COVID-19, The Hill reported.
Read the full article here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
